Eyes on Asia: Tanabe Pharma, KYAN Technologies, Biogen
LEO Pharma agreed to acquire worldwide rights to Tanabe Pharma’s dersimelagon for up to $435m. The late-stage oral drug completed Phase III, with an FDA NDA filed June 2026. Thermo Fisher and KYAN Technologies will collaborate on precision oncology using patient-derived tumoroids. Biogen’s felzartamab won China NMPA approval for multiple myeloma. Expedition Therapeutics raised $115m Series B for EXPD-101 COPD Phase II.
How this was made
.webp%253Fdisable%253Dupscale%2526width%253D1200%2526height%253D630%2526fit%253Dcrop&w=2048&q=75)
The 30-second read
Why it matters
Traders can treat Biogen’s China approval and LEO’s large asset acquisition as higher-conviction catalysts, while Thermo/KYAN’s MoU and Expedition’s Series B are more supportive but less immediately determinative without additional financial terms or clinical readouts.
Market read
This is a multi-catalyst biotech brief: one clear regulatory de-risking event (Biogen), one large late-stage asset acquisition (LEO), one platform collaboration (Thermo/KYAN), and one financing runway extension (Expedition).
What to watch
For LEO’s dersimelagon, FDA approval risk remains high despite Phase III completion; for Biogen, China approval does not guarantee global uptake or pricing power; for Expedition, Series B terms could still imply meaningful dilution.
Background
The article bundles multiple biotech/pharma developments across M&A (LEO/Tanabe), regulatory approval (Biogen felzartamab in China), research collaboration (Thermo Fisher/KYAN), and venture financing (Expedition Therapeutics).
Ticker impact
Biogen’s felzartamab won China approval for multiple myeloma, clearing the CD38 monoclonal antibody via NMPA.
Positive bias for BIIB, with follow-through tied to uptake and any incremental guidance not provided here.
A first regulatory approval in China is a concrete de-risking event and the article also links it to a prior Greater China rights deal.
Thermo Fisher signed an MoU with KYAN Technologies to advance functional precision oncology using tumoroids and sequencing assays.
Limited immediate price impact; more relevant for longer-dated sentiment around oncology platform adoption.
An MoU is typically lower commitment than a binding commercial agreement, and the article provides no financial terms or near-term milestones beyond research activities.
KYAN Technologies is named as the partner in a Thermo Fisher MoU to use KYAN’s Optim.AI platform for donor-specific drug response testing.
Small-to-moderate positive sentiment if investors treat it as platform traction; otherwise negligible.
The article describes technical collaboration details but provides no funding, contract value, or binding commitments, limiting tradable immediacy.
Expedition Therapeutics closed a $115 million Series B to fund Phase II development of EXPD-101 for COPD.
Positive for EXPD on reduced dilution/financing overhang, with follow-through dependent on Phase II readouts.
A disclosed, sizable Series B is a tangible balance-sheet catalyst, though the article does not specify valuation or dilution terms.
Market effects
Reinforces continued capital and strategic interest in rare dermatology (LEO/Tanabe) and CD38 myeloma therapeutics (Biogen), while highlighting growth in precision oncology tooling (Thermo/KYAN).
China NMPA approval for felzartamab is a direct positive for Biogen’s China commercial outlook.
Cross-border licensing and platform collaborations signal ongoing globalization of oncology and rare-disease development pipelines.
Counterpoint
MoUs and financing headlines can be less impactful than they appear; without binding commercial terms or valuation/dilution details, near-term stock moves may fade.
Key entities
- companyLEO Pharma
Agreed to acquire worldwide rights to dersimelagon from Tanabe Pharma for up to $435 million.
- companyTanabe Pharma
Developer of dersimelagon, selling worldwide rights to LEO Pharma.
- companyBiogen
Felzartamab receives first regulatory approval in China for multiple myeloma.
- companyThermo Fisher Scientific
Signed an MoU with KYAN to advance functional precision oncology using tumoroids and sequencing assays.
- companyKYAN Technologies
Provides Optim.AI platform and tumoroid-based functional drug response approach in the collaboration.
